G 1 Therapeutics Inc (GTHX)

Shares of G1 Therapeutics Inc (GTHX) dropped by 35.39% from $3.73 to $2.41 in the trading on Wednesday, December 13, 2023. The reason why GTHX down today is due to a lower-than-expected preliminary results from their ongoing Phase 3 trial evaluating trilacilib in metastatic triple-negative breast cancer. The results showed that triacilb did not meet the primary endpoint of improving overall survival. In addition, an analyst from Needham reinterated Buy rating but cautioned that risks remain until the final analysis is available.